Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
February 21 2024 - 8:01AM
Business Wire
Conference Call Scheduled for Wednesday,
February 28, 2024 at 4:30 p.m. ET.
Revance Therapeutics, Inc. (RVNC), today announced that the
company will release fourth quarter and full year 2023 financial
results on Wednesday, February 28, 2024, after the close of market.
Revance will host a corresponding conference call and a live
webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss
the results and provide a corporate update.
Individuals interested in listening to the conference call may
do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599
for other locations and reference conference ID 643827, or from the
webcast link in the investor relations section of the company's
website at: www.revance.com.
A webcast replay will be available beginning February 28, 2024,
at 4.30 p.m. PT / 7.30 p.m. ET to May 28, 2024, at 4.30 p.m. PT /
7.30 p.m. ET. To access the replay, please register via the webcast
link on the events page. The webcast will be available in the
investor relations section on the company's website for 90 days
following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
enhance patient outcomes and physician experiences. Revance’s
portfolio includes DAXXIFY (daxibotulinumtoxinA-lanm) for injection
and the RHA® Collection of dermal fillers in the U.S. Revance has
also partnered with Viatris Inc. to develop a biosimilar to
onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical
to commercialize DAXXIFY in China.
Revance is headquartered in Nashville, Tenn., with additional
office locations in Newark and Irvine, Calif. Learn more at
Revance.com, RevanceAesthetics.com, DAXXIFY.com,
HCP.DaxxifyTherapy.com, or connect with us on LinkedIn.
“Revance”, the Revance logo, and DAXXIFY are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221311035/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 jessica.serra@revance.com
or
Gilmartin Group, LLC.: Laurence Watts, 619-916-7620
laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Cathryn Castaldo,
615-245-7567 cathryn.castaldo@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jul 2023 to Jul 2024